WALTHAM, Mass., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will
report fourth quarter and full year 2015 financial results on Thursday, February 25, 2016. The Company will issue a press release
before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the
reporting period ended December 31, 2015.
The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers and (404) 537-3372 for
international callers. Participants must provide the passcode 41151742. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will
be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and
(404) 537-3406 for international callers. Replay listeners must provide the passcode 41151742.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value
consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life
sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical
component of Protein A media that is used to separate and purify monoclonal antibody therapeutics. Our ATF System and our growth
factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In addition, we
developed and market an innovative line of “ready-to-use” chromatography columns under our OPUS® brand that we deliver
pre-packed with our customers’ choice of purification media. Repligen’s corporate headquarters are in Waltham, MA (USA) and our
manufacturing facilities are located in Waltham, MA and Lund, Sweden.
This press release may contain forward-looking statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which are not strictly historical statements including, without
limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to
time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any
forward-looking statements, except as required by law.
Repligen Corporation Sondra Newman Senior Director Investor Relations (781) 419-1881 snewman@repligen.com
